Meaning and Methodology of Fundamental Analysis (2025)

Dividend-paying stocks: return, risk, strategy

Balance sheet and income statement made clear 2025

What is a stock exchange? Operation, actors, examples

Stock Valuation 2025: A Beginner's Guide

What does the stock market report section contain?



Before Adobe's Q3 2026 report, the stock price rose by almost 50%, and then began a rapid decline, but those who were clever could realize a 50% price gain in a month and a half with a good entry. With this performance, it earned its place in the "Reporting on the Stock Exchange" column, which is always an update of the fundamental analysis. But what is this all about?



The column is a kind of compass for investors, helping them navigate th

What does the stock market report section contain?



Before Adobe's Q3 2026 report, the stock price rose by almost 50%, and then began a rapid decline, but those who were clever could realize a 50% price gain in a month and a half with a good entry. With this performance, it earned its place in the

Adobe 2026 Q3 – Is sentiment driving the price?

Objective Corporation (ASX:OCL) share fundamentals, overview



Objective Corporation is an Australian software company founded in 1987, specializing in content and records management and regulatory workflow software for government and regulated industry sectors (e.g. defense institutions, military, etc.). The company is still led by founder Tony Walls today, who owns approximately 64.81% of the shares through the TBW Group holding company, one of the highest founder ownership ratios on the Aust

Objective Corporation (ASX:OCL) share fundamentals, overview



Objective Corporation is an Australian software company founded in 1987, specializing in content and records management and regulatory workflow software for government and regulated industry sectors (e.g. defense institutions, military,

Objective Corporation Stock Analysis – State Within State

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

The trust seeks to achieve its investment objective by holding a portfolio of the common stocks that are included in the index (the "Portfolio"), with the weight of each stock in the Portfolio substantially corresponding to the weight of such stock in the index.

Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance

Pfizer Appoints Cecile Guegan as Chief Financial Officer

Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma

Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting

Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026

Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026

Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer

Pfizer Declares Fourth-Quarter 2026 Dividend

Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

Pfizer: The Portfolio Transformation Is Gaining Momentum

Pfizer Q3: The Street Is Pricing In Too Much Deceleration For This 5.7% Yield

United Therapeutics buys out Pfizer royalties linked to lung disease therapy

Pfizer raises 2026 outlook to $62B-$64B revenue and $2.95-$3.05 adjusted EPS, targeting high single-digit revenue CAGR from 2028-2033

Pfizer Inc. (PFE) Q3 2026 Earnings Call Transcript

How health care is on the ballot in the midterms

Pfizer Inc. 2026 Q3 - Results - Earnings Call Presentation

Pfizer hikes 2026 outlook despite flat Q3 revenue: names new CFO

Pfizer in Charts: Primary Care rebounds sharply in Q3, while Oncology extends its growth streak

Earnings Snapshot: Pfizer names Cecile Guegan CFO, raises FY26 outlook after Q3 beat

Pfizer Non-GAAP EPS of $0.87 beats by $0.14, revenue of $16.58B beats by $700M

Pfizer Q3 preview: Analysts look to obesity pipeline amid diverging growth expectations

Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growth

Pfizer: Reality Check Ahead Of Earnings

Pfizer posts late-stage trial win for multiple myeloma drug Elrexfio in an earlier line setting

Pfizer Talzenna/Xtandi combo approved for earlier prostate cancer setting

Pfizer sees strong response for pediatric pneumonia vaccine in mid-stage trial

Keytruda, Padcev combo for bladder cancer approved by European Commission

Lilly, Pfizer, J&J among winners of EU drug recommendations this month

Pfizer: The Earnings Test That Matters

Hospital group files lawsuit to stop 340B rebate pilot again

Dividend Roundup: Starbucks, Pfizer, Micron, AbbVie, and more

Pfizer: Previously Bearish, I'm Converting To A Cautious Bull (Rating Upgrade)

Pfizer to close penicillin unit, cut around 330 jobs in Italy

Pfizer’s Tukysa regimen approved in U.S. for front-line breast cancer

Pharma lobby group sues Trump administration over MFN pricing

State attorneys general sue RFK Jr., seeking to reinstate childhood vaccine schedule

Pfizer declares $0.43 dividend

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

Pfizer says phase 3 data buoys Litfulo as a vitiligo treatment

Covid-19 vaccine comments

segment-revenues

Segment Revenues ($M)

Szegmens Árbevételek ($M)

geographic-revenues

Geographic Revenues ($M)

Bevétel Földrajzi Megoszlás ($M)

Accounts payable

Total current assets

Cash

Short/Current long term debt

Goodwill

Intangible assets

Net tangible assets

Property, plant and equipment

Net receivables

Shareholder's equity

Total assets

Total current liabilities

Total liabilities

Balance Sheet

Capital expenditures (TTM)

Operating cash flow (TTM)

Dividends paid (TTM)

Free cash flow (TTM)

Cash flow

DGR 10 years

DGR 15 years

DGR 3 years

DGR 5 years

DGR MR

DGR TTM

EPS growth (5y forward)

EPS growth (5y)

Time since last change announced

Dividend growth

Average yield

Yield as % of max yield

Discount to avg yield

Dividend per share

Dividend yield

Payout frequency

Maximum yield

Minimum yield

Upside potential

Dividend yield - 5y

Avg time to new high

Avg drop from high

Max time to new high

Highest price drop

Date of highest drop

Current price drop from All-time high

Downside potential

CCC status

Years of growth

EPS (1y forward)

EPS (TTM)

Ex-div date

Cash Return on Invested Capital

Return on Assets

Return on Equity

Return on Invested Capital

Financial returns

Gross profit (TTM)

Net income (TTM)

Operating income (TTM)

Revenue (TTM)

Income statement

Gross margin (TTM)

Operating margin (TTM)

Profit margin (TTM)

Margins

Average

Forward

Payout ratio

FCF per share (TTM)

Current share count

Per share

Current yield distribution

Yield at 0% (Max)

Yield at 10%

Yield at 100% (Min)

Yield at 20%

Yield at 50% (Median)

Yield at 80%

Yield at 90%

Yield distribution (inverse percentile) - 5y

All-time high

1y analyst estimate

Beta

Price at close

Daily high

Daily low

Open

Daily Volume

Next earnings date

Stock chart

EV to Sales

Price to Book

Price to Sales

Valuation (Sales/Book Value)

EV to EBITDA

Trailing P/E

Price to EBITDA

Price to FCF

Price to OCF

Valuation Ratios

PFE

Adobe 2026 Q3 – Is sentiment driving the price?

Business insight

Meaning and Methodology of Fundamental Analysis (2025)

Segment Revenues ($M)

Geographic Revenues ($M)